Evidence map›Paper›PMID 38113004›Full record

ArticleCancer treatment and research2023

Histone Readers and Their Roles in Cancer.

Hong Wen, Xiaobing Shi

Open access · greenAbstract read
In one paragraph

Article in Cancer treatment and research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hong WenVan Andel Institute, 333 Bostwick Ave. NE, Grand Rapids, MI, 49503, USA.
Xiaobing ShiVan Andel Institute, 333 Bostwick Ave. NE, Grand Rapids, MI, 49503, USA. Xiaobing.Shi@vai.org.
Van Andel Institute · US

Funding

Development of Novel PROTACs Targeting the ENL YEATS Domain for Treating MLL-rearranged LeukemiasR01CA260666 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JIN, JIAN, WEN, HONG · 2021 to 2025
$2.5M
Discovery of small molecules targeting the histone acetylation reader ENLR01CA255506 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI WEN, HONG · 2021 to 2024
$1.7M
High Throughput Screen for Inhibitors of the YEATS2 Histone Acylation ReaderR01CA268440 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI SHI, XIAOBING · 2022 to 2025
$1.7M
NCI NIH HHS R01 CA255506NCI NIH HHS R01 CA260666NCI NIH HHS R01 CA268440
6 · The paper itself

Abstract

Histone proteins in eukaryotic cells are subjected to a wide variety of post-translational modifications, which are known to play an important role in the partitioning of the genome into distinctive compartments and domains. One of the major functions of histone modifications is to recruit reader proteins, which recognize the epigenetic marks and transduce the molecular signals in chromatin to downstream effects. Histone readers are defined protein domains with well-organized three-dimensional structures. In this Chapter, we will outline major histone readers, delineate their biochemical and structural features in histone recognition, and describe how dysregulation of histone readout leads to human cancer.

Indexed as

HistonesNeoplasmsChromatinEpigenesis, GeneticHumansProtein Processing, Post-TranslationalChromatinHistones

Identifiers

PMID38113004
PMCPMC11395558
OpenAlexW4389960915

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.